Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Oren Livnat - H.C. Wainwright Andreas Argyrides - Wedbush Greg Fraser - Truist Securities Operator Go ...

• Ex-U.S. market expansion in 2023 • Significant upside in current and new markets 7 EXPAREL Penetration Market Procedures Orthopedics General Surgery Women's Health Cardiothoracic OMFS 18M 1M 3M 6M ~34M 6M Potential Procedures1 slowdown in growth in 2022 %YoY Growth (Moving Annual Total) 2020 vs 2021 2021 vs 2022 2021 2022 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 35 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 W44 W26 YE W26 W44 MAT YoY recovery from 2020 lockdo ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Serge Belanger - Needham Gary Nachman - BMO Capital Markets Susan Mesco Good morning everyone. Welcome to today's conference call to discuss our Third Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) 5401 West Kennedy Boulevard, Suite 890 Tam ...

Pacira Biosciences Inc. (NASDAQ:PCRX) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Chris Neyor - JP Morgan Balaji Prasad - Barclays Gregory Renza - RBC Capital Markets Greg Fraser - Truist Securities Serge Belanger - Needham Operator Ladies and gentlemen, thank you for standing by, and welcome to the Pacira BioScience's Second Quarter 2022 Ear ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Gregory Renza – RBC Capital Markets Greg Fraser – Truist Securities Anita Dushyanth – Berenberg Capital Serge Belanger – Needham & Company Evan Hua – BMO Capital Operator Thank you for standing by, and wel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorpora ...

Table of Contents, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2021 Earnings Conference Call February 24, 2022 8:30 AM ET Company Participants Susan Mesco - Investor Relations Dave Stack - Chairman and Chief Executive Officer Charlie Reinhart - Chief Financial Officer Roy Winston - Chief Medical Officer Conference Call Participants David Amsellem - Piper Sandler Nina Wang - RBC Capital Markets David Steinberg - Jefferies Balaji Prasad - Barclays Capital Christopher Neyor - J.P. Morgan Greg Fraser - Truist Securities Operator Go ...